Windtree Therapeutics has been officially delisted from the Nasdaq Capital Market after failing to meet the exchange’s minimum listing standards, just weeks after announcing a major treasury strategy centered on BNB. The delisting is not connected to the performance of BNB, which recently reached a new all-time high.
Nasdaq Delisting
Nasdaq informed Windtree on August 19 that its stock no longer met the minimum bid price requirement of $1.00. The company’s stock had traded below that threshold for over 30 consecutive business days. As a result, trading was suspended on August 21, and Windtree will now move to the over-the-counter (OTC) market under the ticker WINT.
Windtree’s share price dropped sharply following the notice, falling over 77% to $0.11.
BNB Treasury Plan
In July, Windtree announced a treasury strategy involving the acquisition of BNB, the native token of BNB Chain. The company had signed a $60 million agreement with Build and Build Corp, followed by a $500 million equity line of credit and a $20 million stock-purchase pact, with nearly all proceeds reportedly intended for BNB purchases.
The initiative aimed to position Windtree as one of the first Nasdaq-listed companies to hold BNB as a reserve asset. However, since the announcement, the company has not disclosed how much BNB it actually acquired or whether the treasury plan will continue after the delisting.
We’ve released a full guide to recognizing presale scams!
It covers how these schemes work, how they trap investors – and how to spot the red flags. Check it out here!
BNB Price Unaffected
Despite Windtree’s delisting, BNB’s market performance remains strong. On the same day the delisting was announced, BNB rose over 5% and reached a new all-time high above $880. The token’s price action is completely separateto Windtree’s financial situation.
BNB continues to show strong momentum in both price and trading volume, with broader market sentiment around the token remaining positive.
